Therapeutic options for the management of severe COVID-19: A rheumatology perspective()

The novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). Acute respiratory distress syndrome (ARDS), multiorgan dysfunction and thrombotic events are among the leading causes of death in critically ill patients with COVID-19. The elev...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendoza-Pinto, Claudia, García-Carrasco, Mario, Munguía Realpozo, Pamela, Méndez-Martínez, Socorro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2021
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561336/
https://www.ncbi.nlm.nih.gov/pubmed/34625144
http://dx.doi.org/10.1016/j.reumae.2020.05.002
Descripción
Sumario:The novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). Acute respiratory distress syndrome (ARDS), multiorgan dysfunction and thrombotic events are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a “cytokine storm”, also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. In addition to anti-viral therapy and supportive treatment in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed therapeutic options, including the antibody therapy that might be an immediate strategy for SARS-CoV-2 therapy.

Ejemplares similares